Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Pharvaris N.V. - Ordinary Shares
(NQ:
PHVS
)
29.14
+0.46 (+1.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
89,961
Open
28.50
Bid (Size)
25.00 (100)
Ask (Size)
30.15 (100)
Prev. Close
28.68
Today's Range
28.23 - 29.19
52wk Range
12.94 - 29.85
Shares Outstanding
33,816,459
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors.
↗
April 13, 2026
This clinical-stage biotech focused on rare disease therapies reported a notable insider sale amid a year of sharp share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
Pharvaris NV (NASDAQ:PHVS) Reports Q4 2025 Financial Results and Key Pipeline Milestones
↗
April 02, 2026
Via
Chartmill
Performance
YTD
+10.0%
+10.0%
1 Month
+8.2%
+8.2%
3 Month
+13.7%
+13.7%
6 Month
+33.8%
+33.8%
1 Year
+109.0%
+109.0%
More News
Read More
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
April 02, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
March 20, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
↗
March 18, 2026
Via
The Motley Fool
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
↗
March 18, 2026
Via
The Motley Fool
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
March 11, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
March 02, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
February 10, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
Pharvaris Outlines 2026 Strategic Priorities
January 12, 2026
From
Pharvaris N.V.
Via
GlobeNewswire
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?
↗
December 09, 2025
Via
The Motley Fool
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
↗
December 08, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
PHVS Stock Jumps After Phase 3 Trial Shows Rapid Symptom Relief For Oral HAE Treatment
↗
December 03, 2025
Via
Stocktwits
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
December 03, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
A $68 Million Signal: What General Atlantic Sees in Pharvaris Right Now
↗
December 02, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company
↗
November 29, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million
↗
November 20, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
↗
November 20, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Gets Booted in Latest Fund Update
↗
November 19, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock
↗
November 19, 2025
Via
The Motley Fool
5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity?
↗
November 18, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out
↗
November 18, 2025
Via
The Motley Fool
Why Bain Capital Is Selling Shares of This Biotech Stock Now
↗
November 18, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
November 12, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting
November 10, 2025
From
Pharvaris N.V.
Via
GlobeNewswire
Frequently Asked Questions
Is Pharvaris N.V. - Ordinary Shares publicly traded?
Yes, Pharvaris N.V. - Ordinary Shares is publicly traded.
What exchange does Pharvaris N.V. - Ordinary Shares trade on?
Pharvaris N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Pharvaris N.V. - Ordinary Shares?
The ticker symbol for Pharvaris N.V. - Ordinary Shares is PHVS on the Nasdaq Stock Market
What is the current price of Pharvaris N.V. - Ordinary Shares?
The current price of Pharvaris N.V. - Ordinary Shares is 29.14
When was Pharvaris N.V. - Ordinary Shares last traded?
The last trade of Pharvaris N.V. - Ordinary Shares was at 04/15/26 04:00 PM ET
What is the market capitalization of Pharvaris N.V. - Ordinary Shares?
The market capitalization of Pharvaris N.V. - Ordinary Shares is 985.41M
How many shares of Pharvaris N.V. - Ordinary Shares are outstanding?
Pharvaris N.V. - Ordinary Shares has 985M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
